Agios Pharmaceuticals
(NASDAQ) AGIO
Agios Pharmaceuticals Financials at a Glance
Market Cap
$2.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$66.05M
Net Income (TTM)
-$422.60M
EPS (TTM)
-$7.25
P/E Ratio
-6.07
Dividend
$0.00
Beta (Volatility)
1.23 (Average)
Dividend
$0.00
Beta (Volatility)
1.23 (Average)
Price
$43.97
Volume
2,776,297.803
Open
$39.38
Price
$43.97
Volume
2,776,297.803
Open
$39.38
Previous Close
$44.01
Daily Range
$39.38 - $44.09
52-Week Range
$22.24 - $46.00
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.00
Beta (Volatility)
1.23 (Average)
Price
$43.97
Volume
2,776,297.803
Open
$39.38
Previous Close
$44.01
Daily Range
$39.38 - $44.09
52-Week Range
$22.24 - $46.00
Estimated Earnings Date
Jul 30, 2026
AGIO News
AGIO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Agios Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
540
CEO
Brian M. Goff, MBA
Website
www.agios.comHeadquarters
Cambridge, MA 02139-4169, US
AGIO Financials
Key Financial Metrics (TTM)
Gross Margin
82.07%
Operating Margin
-719.97%
Net Income Margin
-639.84%
Return on Equity
-34.11%
Return on Capital
-37.62%
Return on Assets
-35.66%
Earnings Yield
-16.47%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
59.47M
Volume
2.78M
Avg. Volume
1.15M
Financials (TTM)
Gross Profit
$54.21M
Operating Income
-$475.53M
EBITDA
-$418.36M
Operating Cash Flow
-$380.41M
Capital Expenditure
-$4.32M
Free Cash Flow
-$384.73M
Cash & ST Invst.
$737.04M
Total Debt
$35.75M
Agios Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$20.75M
+137.7%
Gross Profit
$18.06M
+183.9%
Gross Margin
87.07%
N/A
Market Cap
$2.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$5.39M
N/A
Employees
486
N/A
Net Income
-$99.11M
-11.0%
EBITDA
-$97.75M
-11.1%
Quarterly Fundamentals
Total Cash
$737.04M
-17.5%
Total Debt
$35.75M
-32.5%
Accounts Receivable
$16.13M
+382.4%
Inventory
$35.09M
+18.5%
Long Term Debt
$16.94M
-52.6%
Short Term Debt
$18.81M
+9.4%
Return on Assets
-35.66%
N/A
Return on Invested Capital
-42.23%
N/A
Free Cash Flow
-$119.69M
-6.6%
Operating Cash Flow
-$118.92M
-6.7%